Streamlining Dermatology Prior Authorization Automation

Klivira delivers comprehensive dermatology prior authorization automation, integrating seamlessly with existing EMRs to manage complex requirements for biologics, specialty drugs, and procedures like Mohs surgery.

For revenue cycle directors and prior authorization coordinators in dermatology, managing the increasing volume and complexity of prior authorizations for high-cost biologics and specialized procedures presents a significant operational challenge. Klivira's platform is engineered to mitigate these burdens, ensuring faster approvals and reduced administrative overhead.

High-Volume Prior Authorization Categories in Dermatology

Dermatology practices frequently encounter prior authorization requirements for specific high-cost medications and procedures. Key categories include biologics for chronic conditions, specialty topicals, and Mohs surgery, each demanding precise documentation and adherence to payer policies.

Commonly PA-Triggering Treatments and Procedures

Biologics for psoriasis and psoriatic arthritis (e.g., TNF, IL-17, IL-23 inhibitors, oral targeted therapies) [aad-guidelines]
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab, oral JAK inhibitors) [aad-guidelines]
Biologics for hidradenitis suppurativa (e.g., adalimumab, secukinumab) [aad-guidelines]
Mohs micrographic surgery, particularly for non-melanoma skin cancers in cosmetically sensitive areas [aad-guidelines]
Advanced skin cancer treatments, including immunotherapy for melanoma [nccn-guidelines]
Phototherapy, especially when prescribed for home administration

Critical Documentation for Dermatology PAs

Payer requirements for dermatology prior authorizations are stringent, often aligning with clinical guidelines from organizations like the American Academy of Dermatology (AAD) and NCCN. Accurate and complete documentation is paramount to secure approvals and avoid denials.

Key Documentation Requirements for Common Dermatology PAs

For psoriasis/PsA biologics: Diagnosis (PASI/BSA), trial of prior topical/phototherapy/conventional systemic therapies, TB/hepatitis screening, step therapy compliance [aad-guidelines]
For atopic dermatitis biologics: Diagnosis criteria, EASI/SCORAD severity, topical therapy trial, age-appropriate indications [aad-guidelines]
For Mohs surgery: Site, tumor type, prior treatment, conformance with AAD Appropriate Use Criteria (AUC) [aad-guidelines]
For phototherapy: Distinction between clinic-administered versus home phototherapy, prior topical therapy trial

Common Denial Reasons and Workflow Constraints

Dermatology practices frequently encounter denials due to issues like incomplete step therapy documentation or non-compliance with appropriate use criteria. Additionally, the need for periodic re-authorization for chronic biologic treatments and the distinction between medical and pharmacy benefits add layers of complexity to the PA workflow.

Frequent Challenges in Dermatology Prior Authorization

Failure to document step therapy for psoriasis biologics (e.g., prior topical, phototherapy, methotrexate trials)
Mohs AUC mismatch where site or tumor type does not meet indications [aad-guidelines]
Insufficient documentation of disease severity (e.g., missing PASI, EASI, BSA scores)
Gaps in pre-biologic screenings (e.g., TB, hepatitis)
Periodic re-authorization cycles (typically 6-12 months) for chronic biologic therapies
Navigating medical vs. pharmacy benefit routing for self-injection vs. clinic infusion

Klivira's Solution for Dermatology Prior Authorization

Klivira's platform is specifically designed to address the unique challenges of dermatology prior authorization. Our system incorporates AAD-guideline-aware step-therapy logic, automates AUC validation for Mohs surgery, and streamlines periodic re-authorization workflows for chronic biologic treatments, ensuring accurate medical-vs-pharmacy benefit routing. This targeted approach reduces manual effort and accelerates patient access to critical dermatological care.

Frequently asked questions

What types of dermatological treatments commonly require prior authorization?

Prior authorization is frequently required for high-cost biologics used in conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa. Additionally, specialty topicals, Mohs micrographic surgery, and certain advanced skin cancer treatments also fall under common PA requirements.

How does Klivira handle the complex step therapy requirements for psoriasis biologics?

Klivira's platform integrates AAD-guideline-aware step-therapy logic, automating the verification and documentation of prior topical, phototherapy, and conventional systemic therapy trials. This ensures that all necessary prerequisites are met and accurately submitted to payers, reducing denial rates related to step therapy.

Can Klivira assist with Mohs surgery prior authorizations?

Yes, Klivira automates Appropriate Use Criteria (AUC) validation for Mohs surgery, aligning with AAD guidelines. Our system helps ensure that the submitted documentation for tumor type and site meets payer indications, streamlining the approval process for this high-volume procedure.

How does Klivira manage re-authorization for chronic dermatological conditions?

Klivira's platform includes features for managing periodic re-authorization cycles for chronic biologic treatments, typically occurring every 6 or 12 months. This proactive management helps ensure continuous patient access to essential therapies without lapses due to expired authorizations.

Does Klivira differentiate between medical and pharmacy benefit PAs for dermatology drugs?

Yes, Klivira's system is designed to handle medical-vs-pharmacy benefit routing, which is crucial for dermatology drugs that can be administered as self-injections at home (pharmacy benefit) or infusions in a clinic (medical benefit). This ensures the correct PA pathway is followed for each treatment.